Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Jul 7, 2003
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Estimate overall and relapse-free survival of women with early-stage breast cancer receiving adjuvant tamoxifen with or without adjuvant chemotherapy and/or ovarian suppression.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating institution and choice of randomization option.
Postmenopausal women are randomized to the first or second groups.
Randomization for pre- and perimenopausal women is based on the clinician's judgement of appropriate adjuvant therapy (chemotherapy and/or ovarian suppression). Patients may be randomized as foll...
Gender
FEMALE
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Histologically confirmed invasive carcinoma of the breast for which adjuvant systemic therapy is appropriate
- • Stage I, II, or IIIA
- • Pathologically positive or negative nodes
- • Any size primary tumor
- • No edema, peau d'orange, infiltration of the skin, or direct extension to the chest wall
- * Hormone receptor status:
- • Not specified
- PATIENT CHARACTERISTICS:
- Age:
- • Not specified
- Sex:
- • Female
- Menopausal status:
- • Pre-, peri-, or postmenopausal
- Performance status:
- • Not specified
- Hematopoietic:
- • Not specified
- Hepatic:
- • Not specified
- Renal:
- • Not specified
- Other:
- * No prior malignancy except:
- • Basal cell carcinoma
- • Carcinoma in situ of the cervix
- PRIOR CONCURRENT THERAPY:
- Biologic therapy:
- • See Disease Characteristics
- Chemotherapy:
- • See Disease Characteristics
- Endocrine therapy:
- • See Disease Characteristics
- Radiotherapy:
- • Not specified
- Surgery:
- • Not specified
- Other:
- • No prior systemic treatment for breast cancer
About Institute Of Cancer Research, United Kingdom
The Institute of Cancer Research (ICR) in the United Kingdom is a leading cancer research organization dedicated to understanding the biology of cancer and developing innovative therapeutic strategies. Renowned for its pioneering contributions to cancer treatment and prevention, the ICR conducts cutting-edge clinical trials that translate laboratory discoveries into effective clinical applications. Collaborating with a network of academic, clinical, and industry partners, the ICR is committed to advancing cancer research and improving patient outcomes through rigorous scientific inquiry and a patient-centered approach.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, Scotland, United Kingdom
Birmingham, England, United Kingdom
Patients applied
Trial Officials
John R. Yarnold, MD, FRCR
Study Chair
Royal Marsden NHS Foundation Trust
Helena Earl, MBBS, PhD, FRCP
Study Chair
Cancer Research Campaign Clinical Trials Centre
Stanley B. Kaye, MD, FRCP
Study Chair
University of Glasgow
Tim J. Perren, MD
Study Chair
Leeds Cancer Centre at St. James's University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials